Biotech startup update spotlighting early-stage milestones, team expertise, and plans to advance a new therapeutic platform.
Key Takeaways
- Startup received CHF 150,000 from Venture Kick for preclinical proof-of-concept work
- Company is developing an in‑body stem cell therapy to avoid transplantation procedures
- Initial indications target inherited red blood cell disorders with the goal of single injection treatment